Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment
Abstract Migraine significantly impacts quality of life, with eptinezumab emerging as a promising calcitonin gene-related peptide-targeting therapy. Real-world data and clinical trials are crucial for evaluating its safety and effectiveness comprehensively. This study evaluated its safety using a du...
Saved in:
| Main Authors: | Junchen Chen, Shunqiu Huang, Yashi Chen, Cheng Luo, Yong Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-09490-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating Triptan Safety in Pediatric Migraine Management: A Comprehensive Pharmacovigilance Analysis
by: Chen J, et al.
Published: (2025-06-01) -
Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study
by: Damiana Scuteri, et al.
Published: (2025-07-01) -
Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial
by: Piero Barbanti, et al.
Published: (2024-12-01) -
Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01) -
Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)